Menu
PacPremier
Magic Hour
Montecito
Loading...
You are here:  Home  >  'Blincyto'
Latest

Amgen releases 4th quarter earnings

By   /  Thursday, January 30th, 2020  /  Biotech, Earnings, Latest news  /  Comments Off on Amgen releases 4th quarter earnings

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen’s Blincyto gets approval in Japan

By   /  Monday, September 24th, 2018  /  Central Coast Health Watch, East Ventura County, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen’s Blincyto gets approval in Japan

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Europeans OK expanded use of Amgen’s Blincyto

By   /  Wednesday, August 29th, 2018  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on Europeans OK expanded use of Amgen’s Blincyto

The European Commission approved an expanded use for Amgen’s leukemia therapy Blincyto in treating pediatric patients Aug. 29. Based on results from a study of 93 pediatric patients, the approval allows its use in patients a year old or older with a particular type of relapsed or refractory acute lymphoblastic leukemia. “Historically, children with relapsed Read More →

Read More →
Latest

Thousand Oaks biotech giant Amgen details plans for cash

By   /  Friday, April 27th, 2018  /  Central Coast Health Watch, Earnings, East Ventura County, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Thousand Oaks biotech giant Amgen details plans for cash

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen gets FDA approval for Blincyto

By   /  Thursday, March 29th, 2018  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on Amgen gets FDA approval for Blincyto

Shares for Amgen ticked up 50 cents after the company announced March 29 that its cancer drug Blincyto had received U.S. Food and Drug Administration approval to treat patients in their first or second remission. The decision makes Blincyto the first therapy to be approved to treat patients with minimal residual disease, or MRD, the Read More →

Read More →
Latest

FDA gives full approval to Amgen leukemia drug Blincyto

By   /  Tuesday, July 11th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA gives full approval to Amgen leukemia drug Blincyto

Amgen’s leukemia drug Blincyto received full approval from the U.S. Food and Drug Administration on July 11 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. The biotech giant, headquartered in Thousand Oaks, had previously announced that the drug had been fast-tracked for priority review. The full approval includes data Read More →

Read More →
Latest

FDA fast tracks Amgen’s Blincyto leukemia drug

By   /  Thursday, March 30th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on FDA fast tracks Amgen’s Blincyto leukemia drug

Thousand Oaks-based biotech giant Amgen announced March 29 that the U.S. Food and Drug Administration has fast-tracked the company’s leukemia drug Blincyto for priority review. The drug increases the length of survival among high-risk patients, according to a study released by the New England Journal of Medicine. It almost doubled median overall survival versus chemotherapy among adult patients Read More →

Read More →